Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients

Journal of Clinical Oncology

Volumn 20, Issue 1, 2002, Pages 24-36

  Viens, P ^a   Chabannon, C ^a   Pouillard, P ^a   Janvier, M ^a   Brugger, W ^a   Blay, J Y ^a   Oberling, F ^a   Capdeville, R ^a   Newman, C ^a   Meresse V ^a   Xu, Z X ^a   Platzer, E ^a   Van der Auwera, P ^a   Maraninchi, D ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; MESNA; POLYETHYLENE GLYCOL GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT COLONY STIMULATING FACTOR; RO 25 8315; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL COUNT; CELL MOTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LEUKOCYTOSIS; NEUTROPHIL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; STEM CELL; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CONSUMER PRODUCT SAFETY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; NEUTROPHILS; POLYETHYLENE GLYCOLS;

EID: 0036137901     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.1.24     Document Type: Article

References (27)

1. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer
2. Filgrastim (rmetHuG-CSF): The first 10 years
3. Effect of peripheralblood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy
4. Peripheral blood stem cells and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs
5. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients
6. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukemia: First results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation
7. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Société Française de Greffe de Moelle
8. Effect of mutant human granulocyte colony-stimulating factor, KW-2228, on anticancer drug-induced leukopenia in mice
9. In vitro and in vivo hematopoietic effect of mutant human granulocyte colony-stimulating factor
10. The uses and properties of PEG-linked proteins
11. High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer
12. Nordic flow cytometry standards for CD34+ cell enumeration in blood and leukapheresis products: Report from the second Nordic workshop
13. Toward a worldwide standard for CD34+ enumeration?
14. Histological evaluation of three new monoclonal anti-cytokeratin antibodies: 1. Normal tissues
15. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow
16. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer
17. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: First results of a randomised multicenter trial of European Group for Blood and Marrow Transplantation
18. Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus rMetHuGCSF in locally advanced and metastatic breast cancer
19. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans
20. Safety profile of filgrastim (r-metHuG-CSF)
21. Allogeneic blood stem cell transplantation: Considerations for donors
22. Filgrastim postchemotherapy mobilises more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis
23. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitors cells in cancer patients
24. Pharmacology of filgrastim (r-metHuG-CSF)
25. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors
26. Detection and clinical significance of minimal tumour cell contamination of peripheral blood stem cell harvest
27. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: A randomized multicenter study